Roche's Actemra nabs 'breakthrough' tag for new use; Novartis rolls out new Cosentyx data in ankylosing spondylitis;

> Roche ($RHHBY) won the FDA's coveted "breakthrough" designation for a new use for its anti-inflammatory drug Actemra, in patients with systemic sclerosis. Release

> Novartis ($NVS) touted one-year data from its MEASURE 2 study showing that 74% of ankylosing spondylitis patients saw significant, sustained improvement with Cosentyx therapy. Release

> The National Institute for Health and Care Excellence turned down Celgene's ($CELG) psoriasis med Otezla, in contrast to the Scottish Medicines Consortium's decision in favor of the drug. Report

> Life sciences sales specialist Aktana rolled out a new product connecting its decision-making support solution to Veeva Systems' new CRM software. Release (PDF)

And Finally... Johnson & Johnson's ($JNJ) Tylenol brand ID'd Canada's most sleepless cities in a survey to help sell its sleep aids. Report


Suggested Articles

Cardiac risks associated with roxadustat are comparable to placebo in nondialysis patients and to Amgen's standard, Epogen, in those on dialysis.

Pfizer and Merck KGaA's immuno-oncology agent Bavencio failed another gastric cancer study, this time as a maintenance treatment after chemotherapy.

A jury ordered Biogen to pay nearly $6 million to a former sales manager who reported a colleague's misconduct and got fired a few months later.